Search results for "Ovarian Neoplasms"

showing 2 items of 152 documents

Biocompatible Lipid Nanoparticles as Carriers to Improve Curcumin Efficacy in Ovarian Cancer Treatment

2017

Curcumin is a natural molecule with proved anticancer efficacy on several human cancer cell lines. However, its clinical application has been limited due to its poor bioavailability. Nanocarrier-based drug delivery approaches could make curcumin dispersible in aqueous media, thus overtaking the limits of its low solubility. The aim of this study was to increase the bioavailability and the antitumoral activity of curcumin, by entrapping it into nanostructured lipid carriers (NLCs). For this purpose here we describe the preparation and characterization of three kinds of curcumin-loaded NLCs. The nanosystems allowed the achievement of a controlled release of curcumin, the amounts of curcumin r…

nanostructured lipid carriers curcumin drug release cancer epithelial ovarian cellsCurcuminNanoparticleAdministration Oral02 engineering and technologyPharmacologynanostructured lipid carrier03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDrug Delivery SystemsNanoparticleSettore BIO/10 - BiochimicamedicineHumanscancerParticle SizeDrug Carrierdrug releaseCell ProliferationOvarian NeoplasmsDrug CarriersOvarian NeoplasmChemistry (all)General ChemistryLipid021001 nanoscience & nanotechnologyBiocompatible materialmedicine.diseaseControlled releaseLipidsBioavailabilitychemistryAgricultural and Biological Sciences (all)Settore CHIM/09 - Farmaceutico Tecnologico Applicativo030220 oncology & carcinogenesisDrug deliveryCurcuminNanoparticlesFemaleNanocarriers0210 nano-technologyGeneral Agricultural and Biological SciencesOvarian cancerDrug Delivery Systemepithelial ovarian cellHuman
researchProduct

Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations

1999

Two biallelic polymorphisms in introns 3 and 6 of the p53 gene were analysed for a possible risk-modifying effect for ovarian cancer. Germline DNA was genotyped from 310 German Caucasian ovarian cancer patients and 364 healthy controls. We also typed 124 affected and 276 unaffected female carriers with known deleterious BRCA1 or BRCA2 germline mutation from high-risk breast-ovarian cancer families. Genotyping was based on PCR and high-resolution gel electrophoresis. German ovarian cancer patients who carried the rare allele of the MspI restriction fragment length polymorphism (RELP) in intron 6 were found to have an overall 1.93-fold increased risk (95% confidence internal (CI) 1.27–2.91) w…

p53AdultCancer Researchendocrine system diseasesAdolescentGenotypeGenes BRCA1BiologypolymorphismGermline mutationRisk FactorsGenotypemedicineTumor Cells CulturedHumansAlleleAllele frequencyGerm-Line MutationAgedGeneticsAged 80 and overBRCA2 ProteinOvarian NeoplasmsGenetic Carrier ScreeningCancerGenetic VariationRegular ArticleMiddle Agedmedicine.diseaseBRCA2 ProteinBRCA1Genes p53BRCA2IntronsNeoplasm Proteinsovarian cancerOncologyCase-Control StudiesCancer researchFemaleRestriction fragment length polymorphismOvarian cancergenetic susceptibilityTranscription FactorsBritish Journal of Cancer
researchProduct